Therapeutic approaches to non-alcoholic fatty liver disease: past achievements and future challenges

被引:38
作者
Xiao, Jia [1 ,4 ]
Guo, Rui [1 ]
Fung, Man Lung [2 ,3 ]
Liong, Emily C. [1 ]
Tipoe, George L. [1 ,3 ]
机构
[1] Univ Hong Kong, Li Ka Shing Fac Med, Dept Anat, Hong Kong, Hong Kong, Peoples R China
[2] Univ Hong Kong, Li Ka Shing Fac Med, Dept Physiol, Hong Kong, Hong Kong, Peoples R China
[3] Univ Hong Kong, Li Ka Shing Fac Med, Res Ctr Heart Brain Hormone & Hlth Aging Ctr, Hong Kong, Hong Kong, Peoples R China
[4] Chinese Acad Sci, Shenzhen Inst Adv Technol, Gene & Cell Engn Res Ctr, Shenzhen, Peoples R China
关键词
non-alcoholic fatty liver disease; therapy; pharmaceuticals; exercise; PLACEBO-CONTROLLED-TRIAL; HEPATIC INSULIN-RESISTANCE; ACTIVATED PROTEIN-KINASE; COA REDUCTASE INHIBITORS; LIFE-STYLE MODIFICATION; DIET-INDUCED-OBESITY; ALL-CAUSE MORTALITY; VITAMIN-E; ADIPOSE-TISSUE; RISK-FACTORS;
D O I
10.1016/S1499-3872(13)60021-1
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver injury and mortality in Western countries and China. However, as to date, there is no direct and effective therapy for this disease. The aim of this review is to analyze the key progress and challenges of main current therapeutic approaches in NAFLD. DATA SOURCE: We carried out a PubMed search of English-language articles relevant to NAFLD therapy. RESULTS: There are two major therapeutic strategies for NAFLD treatment: (1) lifestyle interventions (including weight reduction, dietary modification and physical exercise) and (2) pharmaceutical therapies. Lifestyle interventions, particularly chronic and moderate intensity exercise, are the most effective and recognized clinical therapies for NAFLD. For pharmaceutical therapies, although their effects and mechanisms have been extensively investigated in laboratory studies, they still need further tests and investigations in clinical human trials. CONCLUSION: Future advancement of NAFLD therapy should focus on the mechanistic studies on cell based and animal models and human clinical trials of exercise, as well as the combination of lifestyle intervention and pharmaceutical therapy specifically targeting main signaling pathways related to lipid metabolism, oxidative stress and inflammation. (Hepatobiliary Pancreat Dis Int 2013;12:125-135)
引用
收藏
页码:125 / 135
页数:11
相关论文
共 123 条
[1]   A pilot trial of pentoxifylline in nonalcoholic steatohepatitis [J].
Adams, LA ;
Zein, CO ;
Angulo, P ;
Lindor, KD .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (12) :2365-2368
[2]   Overview of metformin: special focus on metformin extended release [J].
Ali, Shamsa ;
Fonseca, Vivian .
EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (12) :1797-1805
[3]   Non-alcoholic fatty liver disease and metabolic syndrome in adolescents: Pathogenetic role of genetic background and intrauterine environment [J].
Alisi, Anna ;
Cianfarani, Stefano ;
Manco, Melania ;
Agostoni, Carlo ;
Nobili, Valerio .
ANNALS OF MEDICINE, 2012, 44 (01) :29-40
[4]   Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis [J].
Athyros, Vasilios G. ;
Tziomalos, Konstantinos ;
Gossios, Thomas D. ;
Griva, Theodora ;
Anagnostis, Panagiotis ;
Kargiotis, Konstantinos ;
Pagourelias, Efstathios D. ;
Theocharidou, Eleni ;
Karagiannis, Asterios ;
Mikhailidis, Dimitri P. .
LANCET, 2010, 376 (9756) :1916-1922
[5]   Effect of exercise and dietary modification on serum aminotransferase levels in patients with nonalcoholic steatohepatitis [J].
Baba, CS ;
Alexander, G ;
Kalyani, B ;
Pandey, R ;
Rastogi, S ;
Pandey, A ;
Choudhuri, G .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 (01) :191-198
[6]   Regular Exercise Is Associated with a Reduction in the Risk of NAFLD and Decreased Liver Enzymes in Individuals with NAFLD Independent of Obesity in Korean Adults [J].
Bae, Ji Cheol ;
Suh, Sunghwan ;
Park, Se Eun ;
Rhee, Eun Jung ;
Park, Cheol Young ;
Oh, Ki Won ;
Park, Sung Woo ;
Kim, Sun Woo ;
Hur, Kyu Yeon ;
Kim, Jae Hyeon ;
Lee, Myung-Shik ;
Lee, Moon Kyu ;
Kim, Kwang-Won ;
Lee, Won-Young .
PLOS ONE, 2012, 7 (10)
[7]   Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos Nutrition and Liver Study [J].
Bedogni, G ;
Miglioli, L ;
Masutti, F ;
Tiribelli, C ;
Marchesini, G ;
Bellentani, S .
HEPATOLOGY, 2005, 42 (01) :44-52
[8]   A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis [J].
Belfort, Renata ;
Harrison, Stephen A. ;
Brown, Kenneth ;
Darland, Celia ;
Finch, Joan ;
Hardies, Jean ;
Balas, Bogdan ;
Gastaldelli, Amalia ;
Tio, Fermin ;
Pulcini, Joseph ;
Berria, Rachele ;
Ma, Jennie Z. ;
Dwivedi, Sunil ;
Havranek, Russell ;
Fincke, Chris ;
DeFronzo, Ralph ;
Bannayan, George A. ;
Schenker, Steven ;
Cusi, Kenneth .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (22) :2297-2307
[9]   RETRACTED: Hepatic Glucagon Action Is Essential for Exercise-Induced Reversal of Mouse Fatty Liver (Retracted article. See vol. 65, pg. 2463, 2016) [J].
Berglund, Eric D. ;
Lustig, Daniel G. ;
Baheza, Richard A. ;
Hasenour, Clinton M. ;
Lee-Young, Robert S. ;
Donahue, E. Patrick ;
Lynes, Sara E. ;
Swift, Larry L. ;
Charron, Maureen J. ;
Damon, Bruce M. ;
Wasserman, David H. .
DIABETES, 2011, 60 (11) :2720-2729
[10]   Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? [J].
Bhatia, Lokpal S. ;
Curzen, Nicholas P. ;
Calder, Philip C. ;
Byrne, Christopher D. .
EUROPEAN HEART JOURNAL, 2012, 33 (10) :1190-+